Named among the Southern California Rising Stars for Mergers & Acquisitions.Super Lawyers Magazine, 2015, 2016, and 2017

Daniel E. Rees

Orange County
  • 650 Town Center Drive
  • 20th Floor
  • Costa Mesa, CA 92626-1925
  • USA
 
 

Daniel Rees is a partner and a member of the firm's Corporate Department and Recruiting Committee.

Mr. Rees’ practice encompasses mergers and acquisitions, capital markets, corporate governance, and securities law matters. Within his M&A practice, Mr. Rees has advised corporate and financial buyers and sellers in public and private transactions. Additionally, Mr. Rees has represented issuers and investment banking firms in public and private securities offerings. Mr. Rees regularly provides general representation to public and private company clients in connection with corporate and securities law compliance matters. 

Mr. Rees’ representative transactions include advising:

Mergers & Acquisitions

  • Impact Biomedicines in its sale to Celgene for up to US$7 billion in upfront cash and contingent regulatory approval and sales-based milestones
  • ICU Medical in its US$900 million acquisition of the Hospira Infusion Systems business of Pfizer
  • Air Medical Resource Group in its sale to Air Medical Group Holdings
  • Allergan (fka Actavis) in its:
    • US$40.5 billion Global Generic Pharmaceuticals Business sale to Teva 
    • US$73 billion sale to Actavis
    • US$54 billion hostile takeover attempt by Valeant Pharmaceuticals International (and associated proxy contest lead by Pershing Square and Bill Ackman)
  • PIMCO in its acquisition of Gurtin Municipal Bond Management 
  • ST Telemedia in CenturyLink's US$34 billion acquisition of Level 3 Communications, Inc.  
  • J.P. Morgan as financial advisor to Intralinks Holdings in its US$821 million sale to Synchronoss Technologies
  • Waypoint in its sale of its management platform to Starwood
  • Akebia Therapeutics in its merger of equals with Keryx Biopharmaceuticals
  • Medicis Pharmaceutical in its US$2.6 billion sale to Valeant Pharmaceuticals
  • Complete Production Services in its US$6.2 billion combination with Superior Energy Services
  • Golden State Foods in the sale of its McDonald's food distribution business to Martin Brower 
  • Starbucks in the US$384 million sale of its Tazo tea business 
  • Incipio in its acquisition of Incase
  • Quality Systems in its acquisition of Mirth Corporation
  • 5.11 Tactical in its acquisition of Beyond Clothing
  • Paul Frank in its sale to Saban Brands
  • California Creative Brands in its sale to Sabra

Capital Markets

  • Landmark Infrastructure Partners LP in its IPO of common stock and other securities offerings 
  • Aratana Therapeutics in its IPO of common stock
  • Skullcandy in its IPO of common stock
  • Raptor Pharmaceutical and CoreCivic in “at-the-market” offerings of common stock
  • CoreCivic in offerings of registered debt securities
  • Realty Income Corporation in equity offerings of common stock
  • CoreLogic in 144A offerings of senior notes
  • ICU Medical in secondary offerings of common stock
  • Bank of America Merrill Lynch, Citigroup, Goldman Sachs, Jefferies, J.P. Morgan, Leerink, and Piper Jaffray in follow-on offerings or IPOs, by Corium, Inogen, Glaukos, Green Plains Renewable Energy, MAKO Surgical, Sientra, and YM BioSciences
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.